No Data
No Data
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?
Promising Outlook for Larimar Therapeutics: Buy Rating on Nomlabofusp's Potential in Treating Friedreich's Ataxia
Promising Developments and Financial Strength Support Buy Rating for Larimar Therapeutics
JonesTrading Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $14
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $10
Truist Financial Maintains Larimar Therapeutics(LRMR.US) With Buy Rating
felixfella OP : couldn't go up if it was riding on a airplane...